التفاصيل البيبلوغرافية
| العنوان: |
Aplastic anemia and paroxysmal nocturnal hemoglobinuria in children and adults in two centers of Northern Greece. |
| المؤلفون: |
Gavriilaki, Eleni, Tragiannidis, Athanasios, Papathanasiou, Maria, Besikli, Sotiria, Karvouni, Paraskevi, Douka, Vassiliki, Paphianou, Eleni, Hatzipantelis, Emmanuel, Papaioannou, Giorgos, Athanasiadou, Anastasia, Marvaki, Anastasia, Panteliadou, Alkistis-Kira, Vardi, Anna, Batsis, Ioannis, Syrigou, Antonia, Mallouri, Despina, Lalayanni, Chrysavgi, Sakellari, Ioanna |
| المصدر: |
Frontiers in Oncology; 11/10/2022, Vol. 12, p1-8, 8p |
| مصطلحات موضوعية: |
PAROXYSMAL hemoglobinuria, APLASTIC anemia, BLOOD diseases, BONE marrow, ANEMIA treatment, FANCONI'S anemia |
| مصطلحات جغرافية: |
GREECE |
| مستخلص: |
Bone marrow failure (BMF) syndromes are a group of various hematological diseases with cytopenia as a main common characteristic. Given their rarity and continuous progress in the field, we aim to provide data considering the efficiency and safety of the therapeutic methods, focusing on the treatment of aplastic anemia(AA) and paroxysmal nocturnal hemoglobinuria (PNH). We enrolled consecutive patients diagnosed with BMF in two referral centers of Northern Greece from 2008 to 2020. We studied 43 patients with AA (37 adults and 6 children/adolescents) and 6 with classical PNH. Regarding classical PNH, 4 patients have received eculizumab treatment with 1/4 presenting extravascular hemolysis. Among 43 patients with aplastic anemia, PNH clones were detected in 11. Regarding patients that did not receive alloHCT (n=15), 14/15 were treated with ATG and cyclosporine as first line, with the addition of eltrombopag in patients treated after its approval (n=9). With a median follow-up of 16.7 (1.8-56.2) months from diagnosis, 12/14 (85.7%) are alive (4-year OS: 85.1%). AlloHCT was performed in 28 patients. Five patients developed TA-TMA which did not resolve in 3/5 (all with a pre-transplant PNH clone). With the follow-up among survivors reaching 86.3 (6.3-262.4) months, 10-year OS was 56.9%, independently associated with PNH clones after adjusting for age (p=0.024). In conclusion, our real-world experience confirms that novel treatments are changing the field of BMF syndromes. Nevertheless, there is still an unmet need to personalize algorithms in this field. [ABSTRACT FROM AUTHOR] |
|
Copyright of Frontiers in Oncology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder